RetinalGeniX Technologies, Inc. operates as a medical device company. The company is headquartered in Petaluma, California. The company went IPO on 2022-01-07. The firm's proprietary High-Resolution Retinal Imaging and DNA/RNA/GPS Pharmaco-Genetic Mapping technologies are designed to help prevent blindness by detecting initial physiological changes that could indicate future ocular and systemic diseases affecting neurodegenerative, cardiovascular, vascular and metabolic systems, as well as diabetic conditions, Alzheimer’s disease and Parkinson’s disease. Its RetinalCam is an in-home/remote location patient-activated monitoring and imaging device offering real-time communication and alerting system for physicians available 24/7. The company is also engaged in the development of its product candidates: RTG-2023 and RTG-2024. RTG-2023 for the treatment of dry age-related macular degeneration (dry AMD). RTG-2024 for the treatment of Alzheimer’s syndrome dementia.
RetinalGenix Technologies Inc의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
RetinalGenix Technologies Inc 주요 수익원은 Applications Processors이며, 최신 수익 발표에서 수익은 1,169,616,000입니다. 지역별로는 United States, Mexico, and Venezuela이 RetinalGenix Technologies Inc의 주요 시장이며, 수익은 1,100,858,000입니다.
RetinalGenix Technologies Inc은 수익성이 있나요?
no, 최신 재무제표에 따르면 RetinalGenix Technologies Inc의 순손실은 $0입니다.